We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Fluidigm

Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, imm... read more Featured Products: More products

Download Mobile App




Genetic Test Improves Prognosis for Esophageal Cancer

By LabMedica International staff writers
Posted on 13 Jul 2014
The genetic basis of why some people with a serious complication of acid reflux known as Barrett's esophagus go on to develop esophageal cancer has been determined. More...


A novel noninvasive test could detect esophageal cancer much earlier, thereby improving the prognosis of what is currently a cancer with a poor survival rate. Esophageal cancer makes up about 1% of all cancers diagnosed in the USA, where estimates suggest that in 2014, about 18,170 people will discover they have the cancer, and about 15,450 will die of it.

A consortium of international scientists led by those at University of Cambridge (UK) and collaborating with the University of Southampton (UK) sequenced the DNA of patients with Barrett's esophagus and patients with esophageal cancer (EAC), and mapped out their genetic similarities and differences.

The team used a "non-endoscopic" test to identify high-risk Barrett's esophagus by retrieving cells from the affected part of the esophagus that could then be checked for presence of the mutated genes. The "non-endoscopic" test is called the cytosponge, or "sponge-on-a-string" test, and involves the patient swallowing a capsule containing a sponge attached to a thread. When the capsule reaches the stomach it dissolves, releasing the sponge, which collects cells from the esophagus wall as it is pulled out by the clinician or nurse.

Mutation validation was performed in a cohort of 90 EACs and 109 Barrett's esophagus biopsies, including 43 Barrett's esophagus biopsies with histopathologically confirmed high-grade dysplasia (HGD) and 66 with no dysplasia. The Access Array microfluidics polymerase chain reaction (PCR) platform (Fluidigm; South San Francisco, CA, USA) together with high-throughput sequencing (Illumina; San Diego, CA, USA) was used for targeted resequencing.

The scientists found mutations in the genes tumor protein 53 (TP53) and SMAD family member 4 (SMAD4) that offered a way of identifying patients in which Barrett's esophagus is progressing into cancer. Although the cytosponge is still under development, the investigators believe it could be used to look for mutations in TP53 and SMAD4 to identify patients with early stage esophageal cancer.

There are two types of esophageal cancer, adenocarcinoma and squamous cell carcinoma. People with Barrett's esophagus, a condition that can develop from prolonged, untreated acid reflux or heartburn have a higher risk of developing adenocarcinoma of the esophagus. Tim Underwood, MBBS, PhD, FRCS, a clinician scientist and esophageal surgeon and coauthor of the study said, “This is a landmark study into the genetic basis of why and how some people with Barrett's esophagus get esophageal cancer and others do not. It is still early, but we very much hope that this information will lead to a game-changer for a cancer with one of the worst outcomes.” The study was published on June 22, 2014, in the journal Nature Genetics.

Related Links:

University of Cambridge
University of Southampton
Fluidigm


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mumps Test
ReQuest MUMPS IgM Assay
New
Hepatitis A Rapid Test
Anti-HAV IgM Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: A biomarker discovery pipeline has shown promise as a noninvasive method of diagnosing CRC (Photo courtesy of NCI Center for Cancer Research)

Machine Learning Tool Enables Noninvasive Diagnosis and Monitoring of Colorectal Cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States when considering both genders. Colonoscopy remains the gold standard for CRC diagnosis, but it is invasive,... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.